These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16470114)

  • 1. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.
    Verity EE; Williams LA; Haddad DN; Choy V; O'Loughlin C; Chatfield C; Saksena NK; Cunningham A; Gelder F; McPhee DA
    AIDS; 2006 Feb; 20(4):505-15. PubMed ID: 16470114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis.
    Takefman DM; Sullivan BL; Sha BE; Spear GT
    Virology; 1998 Jul; 246(2):370-8. PubMed ID: 9657955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates.
    Darden JM; Polonis VR; deSouza MS; Chantakulkij S; Brown AE; Birx DL; Pattanapanyasat K
    Cytometry; 2000 Jun; 40(2):141-50. PubMed ID: 10805934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection.
    Vieillard V; Costagliola D; Simon A; Debré P;
    AIDS; 2006 Sep; 20(14):1795-804. PubMed ID: 16954720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
    Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
    J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
    Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
    Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
    Koup RA; Safrit JT; Weir R; Gauduin MC
    Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2.
    Wu X; Okada N; Momota H; Irie RF; Okada H
    J Immunol; 1999 Jan; 162(1):533-9. PubMed ID: 9886430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals.
    Kantakamalakul W; Pattanapanyasat K; Jongrakthaitae S; Assawadarachai V; Ampol S; Sutthent R
    J Immunol Methods; 2006 Aug; 315(1-2):1-10. PubMed ID: 16884734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
    Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
    J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.
    Johansson S; Goldenberg DM; Griffiths GL; Wahren B; Hinkula J
    AIDS; 2006 Oct; 20(15):1911-5. PubMed ID: 16988511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
    Sullivan BL; Takefman DM; Spear GT
    Virology; 1998 Sep; 248(2):173-81. PubMed ID: 9721226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.